Talk:Lipid hypothesis

This is the talk page for discussing improvements to the Lipid hypothesis article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Archives: 1

This article was previously nominated for deletion. The result of the discussion was Keep.

Medicine C‑class High‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
C	This article has been rated as C-class on Wikipedia's content assessment scale.
High	This article has been rated as High-importance on the project's importance scale.

No longer a hypothesis

In 2019, the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) stated that clinical trials and human Mendelian randomization studies have demonstrated the role of LDL-C and LDL-CApoB-containing lipoproteins in atherosclerotic plaque formation and cardiovascular events. LDL-C is causally related to ASCVD. This is no longer a hypothesis but considered as fact:

Furthermore, these clinical trials have clearly indicated that the lower the achieved LDL-C values, the lower the risk of future cardiovascular (CV) events, with no lower limit for LDL-C values, or ‘J’-curve effect... Human Mendelian randomization studies have demonstrated the critical role of LDL-C, and other cholesterol-rich ApoB-containing lipoproteins, in atherosclerotic plaque formation and related subsequent CV events. Thus, there is no longer an ‘LDL-C hypothesis’, but established facts that increased LDL-C values are causally related to ASCVD, and that lowering LDL particles and other ApoB-containing lipoproteins as much as possible reduces CV events. [1]

This is supported by another recent textbook overview

The first and most relevant update presented in the 2019 guidelines concerns the old concept of an “LDL-C hypothesis,” which is now replaced by the established causal role of elevated LDL-C levels in ASCVD. Besides this causal role, genetic studies have introduced the concept of exposure time, revealing that LDL-C also has a cumulative effect on the risk of ASCVD9, a longer-term exposure leads to a greater retention over time of LDL particles (or, more generally, proatherogenic apoB-containing particles) in the arterial wall. Thus, the overall effect of LDL-C level on ASCVD risk is determined by the combination of both plasma levels and time of exposure. [2]

The article should be updated with the recent guidelines position. Psychologist Guy (talk) 15:23, 23 January 2024 (UTC)[reply]

The article title should change, too. There is also a category named "Lipid hypothesis" which would also need changes. What name would you suggest for both? CarlFromVienna (talk) 08:56, 29 January 2024 (UTC)[reply]